news
May 3, 2024

FDA Grants Third Orphan Drug Designation for OS2966

STAMFORD, CONNECTICUT, January 10, 2023. Research at Children’s Hospital Los Angeles has resulted in a novel therapeutic receiving orphan drug status from the Food and Drug Administration (FDA) for the…
Onco_staff
0
news
April 16, 2021

OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma

STAMFORD, CONNECTICUT, March 9, 2021. OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the first patient was treated in…
Onco_staff
2
news
November 17, 2020

OncoSynergy Launches Phase I Trial for Patients With Recurrent Glioblastoma

STAMFORD, CONNECTICUT, November 17, 2020. OncoSynergy, a patient-focused biotech startup founded by physicians trained in neurosurgery has opened enrollment in their phase 1 trial which will study OS2966, a novel…
Onco_staff
0
news
January 24, 2020

OncoSynergy Receives $300K STTR Grant to Develop Novel Oncolytic Virus

GREENWICH, CONNECTICUT (PRWEB), January 14, 2020. OncoSynergy, Inc., a patient-focused oncology company committed to advancing therapeutics to address dire unmet medical needs, announces today that the company has been awarded…
Onco_staff
0
news
April 26, 2019

FDA Acceptance of IND Application for Phase I Trial of OS2966 in Patients with Recurrent Glioblastoma

GREENWICH, CONNECTICUT (PRWEB), April 02, 2019. OncoSynergy, Inc., a patient-focused oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the U.S. Food and Drug…
onco_admin
0
news
February 25, 2019

OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma

GREENWICH, CONNECTICUT, February 25, 2021. OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer.…
onco_admin
0
news
May 8, 2018

OncoSynergy raises Series A Round

SAN FRANCISCO, California (PRWEB), May 04, 2018. OncoSynergy, an oncology therapeutics spinout from UCSF and current resident of the prestigious JLABS South San Francisco incubator, announced that it has closed…
onco_admin
3
news
June 20, 2017

OncoSynergy and Infuseon Therapeutics Partner to Combat Glioblastoma

SAN FRANCISCO, California, June 20, 2017. Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a novel delivery device,…
Onco_staff
0
news
May 9, 2016

OncoSynergy Appoints Oncology Drug Development Veteran Jean Pierre Bizzari, MD to Scientific Advisory Board

SAN FRANCISCO, California, May 10, 2016. OncoSynergy, Inc., a biopharma company developing a novel class of therapies for oncology, Resistance Mechanism Inhibitors (RMIs), announced today that it has appointed former…
onco_admin
0
news
March 17, 2015

FDA Grants Second Orphan Drug Designation for OS2966

SAN FRANCISCO, California, January 20, 2015.  OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for OS2966 in the treatment of ovarian cancer.…
onco_admin
1
newsUncategorized
December 16, 2014

OncoSynergy and CMC partner to combat Ebola

SEATTLE, SAN FRANCISCO, COPENHAGEN (Denmark), and STRASBOURG (France), December 16, 2014. Experimental monoclonal antibody to be used in clinical trials with patients in West Africa infected with the Ebola virus. Recent…
onco_admin
0
news
August 12, 2014

Orphan Drug Designation Obtained for OS2966

SAN FRANCISCO, PRNewswire-iReach, August 12, 2014. OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing…
onco_admin
0
news
June 29, 2014

Emerging Company Profile in BioCentury, The Bernstein Report

OncoSynergy and our lead therapeutic program, OS2966, were featured in an 'Emerging Company Profile' in BioCentury, The Bernstein Report on BioBusiness. See pdf 061614_ECP_OncoSynergy The Bernstein Report is the flagship weekly…
onco_admin
0
news
December 17, 2013

OncoSynergy and CMC Biologics Enter into Agreement for OS2966 Drug Program

OncoSynergy and CMC Biologics enter into agreement to develop and manufacture material for IND enabling studies and phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody drug…
onco_admin
0
news
November 22, 2013

Translational Research Award at World Federation of Neuro-Oncology Meeting

OncoSynergy collaborator, Manish K. Aghi, MD, PhD, Associate Professor of Neurosurgery at University of California at San Francisco, was awarded the Young Investigator Award for Basic/Translational Research at the 4th…
onco_admin
0
news
October 30, 2013

OncoSynergy Highlighted in Startup Portraits

OncoSynergy highlighted in Startup Portraits feature of services provider, Science Exchange. Science Exchange is an online marketplace for outsourcing science experiments. OncoSynergy uses this platform extensively to dramatically increase our research…
onco_admin
0
news
October 9, 2013

Martin Karplus Awarded the 2013 Nobel Prize in Chemistry

Martin Karplus, a co-inventor of key OncoSynergy technologies, awarded the 2013 Nobel Prize in chemistry. Professor Karplus is the Theodore William Richards Professor of Chemistry Emeritus at Harvard and Visiting…
onco_admin
0